Stem Cell Therapy In Utero

An upcoming clinical trial aims to correct for a disease of fragile bones in affected babies before they are born.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

CollagenWIKIMEDIA, NEVIT DILMENResearchers in Sweden and the U.K. have announced that they will begin a stem cell clinical trial in several months to treat brittle bone disease, a rare disorder that causes frequent bone fractures, impaired growth, and even death. The plan is to deliver stem cells that will produce collagen and strengthen bones—half of the babies will receive the therapy in utero, the other half shortly after birth.

One child, now 13, has already received the stem cells and Cecilia Götherström, who is leading the study at Sweden’s Karolinska Institute, said in a press release that the patient is doing well and still growing. Her team’s study will be the first to try the stem cell treatment in the womb. “[W]e believe that we can improve the treatment for other patients by administering it to the foetus and again in repeated doses during the child’s first years of life.”

Dusko Ilic, a stem cell researcher at King’s College London, told BBC News that “any attempt to help the patients suffering this terrible, debilitating disease is more than welcome.” He also pointed out a potential limitation of the study, regarding the fact that people ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies